por
Gus Iversen, Editor in Chief | January 24, 2025
A MEVION S250-FIT proton therapy system has been delivered to Stanford Health Care, marking the first time a proton therapy system will be housed in a conventional linear accelerator (LINAC) vault.
Manufactured in Littleton, Massachusetts, the self-shielded system is the only proton accelerator built in the United States. Its transport to the National Cancer Institute (NCI)-designated Comprehensive Cancer Center was completed via standard highway methods, highlighting the system’s practicality.
The system features MARIE upright patient positioning from Leo Cancer Care, which incorporates a diagnostic CT scanner for enhanced patient comfort and improved management of organ motion during treatment. It will operate at Stanford Health Care with RayStation software.
MEVION S250-FIT is not currently available for clinical use.
“This achievement underscores Mevion’s commitment to advancing proton therapy accessibility by developing systems that seamlessly integrate into existing radiation oncology workflows,” said Tina Yu, CEO and president of Mevion Medical Systems. “Stanford’s leadership in cancer care and innovation makes it ideal for this groundbreaking project.”
Stanford Health Care has a history of pioneering cancer treatments, including the development of the modern radiation therapy LINAC. Sridhar Seshadri, senior vice president and president of Stanford’s Cancer Center, emphasized the importance of this collaboration in advancing cancer care. “The ability to integrate this system into an existing LINAC vault will enable us to expand access to proton therapy,” he said.
Analysis from ResearchAndMarkets indicates the U.S. proton therapy market, valued at $1.04 billion in 2024, is
forecast to reach $2.67 billion by 2033, representing a compound annual growth rate (CAGR) of 10.97%. The growth is attributed to increasing incidence of cancer, technological advancements in proton therapy, and broader insurance coverage.
The MEVION S250-FIT was
initially unveiled at the 2022 American Society of Radiation Oncology meeting.